BRIEF-Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Reuters
28 May
BRIEF-Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

May 28 (Reuters) - Rezolute Inc RZLT.O:

  • REZOLUTE ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 3 SUNRIZE STUDY OF ERSODETUG IN PATIENTS WITH CONGENITAL HYPERINSULINISM

  • REZOLUTE INC - TOPLINE DATA ANTICIPATED IN DECEMBER 2025

  • REZOLUTE INC - ANTICIPATES BLA SUBMISSION FOR ERSODETUG IN 2026

Source text: ID:nGNX5yHBdh

Further company coverage: RZLT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10